Paclitaxel-Coated Versus Uncoated Balloon for Treatment of Below-the-Knee In-Stent-Restenosis (BAIR)
|ClinicalTrials.gov Identifier: NCT01398033|
Recruitment Status : Withdrawn (Study stopped due to lack of patient inclusion)
First Posted : July 20, 2011
Last Update Posted : August 5, 2015
There is both a poor life expectancy and a poor prognosis of limb salvage in those patience with stenoses or occlusions of the lower limb. To date only a small number of these patients could be helped through medication or surgery. The indications for stent placement are poor primary results following percutaneous transluminal angioplasty or evidence of a flow-limiting dissection. The primary success rate after a stent placement is between 80% and 90%. One so far inconsistent discussed problem is the occurrence of in-stent restenosis which is expected in 20% to 78% of treated lesions, depending on the stent used. Using only percutaneous transluminal angioplasty for treatment of an in-stent restenosis, restenosis reoccurs in 70% to 80% of cases.
The aim of this study is to analyse the primary success and the long term results of angioplasty using the drug-coated balloon (paclitaxel) compared to an non-coated balloon in the treatment of in-stent restenosis of lower limb arteries.
|Condition or disease||Intervention/treatment||Phase|
|In-stent Stenosis of Infrapopliteal Arteries||Device: paclitaxel-coated balloon Device: non-coated balloon||Phase 3|
In this prospective, double-blind, randomised, multi-centre study the use of the already certified coated balloon and an uncoated balloon is evaluated in patients with in-stent restenoses/reocclusions of the lower limb artery. The whole lesion length should be covered by the balloon so that proximal and distal overlap of the lesion by a minimum of 5mm is assured. Based on the current literature the average restenoses rate of the lower limb arteries after percutaneous transluminal angioplasty of an in-stent restenosis is 70% after 6 months. Assuming the restenosis rate reduces to 30% after percutaneous transluminal angioplasty using a drug-coated balloon, with a significance level of Alpha=0.05 (bilateral) and a power Beta=0.8, the enrolment of 100 patients is required in order to show a significant difference between treatment groups, considering a dropout rate of 30%. The choice of treatment will be distributed in a randomised, double blind procedure.
The study duration per patient is 2 years. Clinical follow-up evaluations will take place after 3 and 6 months and after 1 and 2 years. After 3 month and 12 months an angiography of the target vessel will be performed.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Paclitaxel-Coated Versus Uncoated Balloon for Treatment of Below-the-Knee In-Stent-Restenosis|
|Study Start Date :||April 2012|
|Estimated Primary Completion Date :||September 2013|
|Estimated Study Completion Date :||September 2014|
Active Comparator: Drug-coated balloon
Device: paclitaxel-coated balloon
Balloon is coated with paclitaxel in a concentration of 3µg/mm2.
Placebo Comparator: non-coated balloon
Treatment of the target lesion with plain balloon angioplasty.
Device: non-coated balloon
percutaneous transluminal angioplasty with a non-coated balloon
- primary patency of target lesion assessed by quantitative angiography [ Time Frame: 3 months after index procedure ]
- Secondary patency of the target lesion assessed by quantitative angiography [ Time Frame: 12 months after index procedure ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01398033
|Herzzentrum Bad Krozingen|
|Bad Krozingen, Germany, 79219|
|Principal Investigator:||Aljoscha Rastan, M.D.||Herzzentrum Bad Krozingen|